Nilo Therapeutics
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics: Series A Funding Round
Nilo Therapeutics has successfully raised $101M in Series A funding, reaching a valuation of $450M.
Company Overview
Developing therapies based on neuro-immunology research
Funding Details
The Series A round was led by Boxer Capital, with participation from Perceptive Advisors.
Company Information
- Headquarters: New York, NY
- Founded: 2023
- Employees: 60+
- Category: Biotech
Investment
Nilo Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Boxer Capital: Verified investor in Series A
- Perceptive Advisors: Verified investor in Series A
Company Info
Investors (2)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free